2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1141

Response To H. Pylori Treatment and Autoantibody In Chronic Thrombocytopenia
Abstract Number: 2467

Response to Tumor Necrosis Factor inhibitors In Axial Spondyloarthritis: Does Sacroiliitis Make Any Difference?
Abstract Number: 2134

Responsiveness and Predictive Ability Of The Knee Society Scale (KSS) Score
Abstract Number: 1553

Responsiveness Of Health Related Quality Of Life Questionnaires To Treatment With Anti-TNF Therapy In Psoriatic Arthritis
Abstract Number: 2275

Responsiveness Of The Outcomes Measures In Rheumatology Clinical Trials Initiative’s Preliminary Flare Questions To Detect Flares Within Patients In The Canadian Early Arthritis Cohort
Abstract Number: 306

Responsiveness To Change Of a Global Ultrasound Assessment Score In Psoriatic Arthritis Patients
Abstract Number: 2854

Restricting Back Pain and Subsequent Mobility Disability In Community-Living Older Persons
Abstract Number: 877

Results From The RATE-RA Study: A Multicenter, Single-Arm Study To Evaluate The Safety Of Administering Rituximab At a More Rapid Infusion Rate In Patients With Rheumatoid Arthritis
Abstract Number: 434

Results Of 64 Weeks Of Treatment With An Anti-IL-17 Antibody, Ixekizumab, In Patients With Rheumatoid Arthritis In a Phase 2 Study
Abstract Number: 278

Results Of a 24 Month Extension Study In Patients Who Participated In The Trial Of Early Aggressive Therapy In Polyarticular Juvenile Idiopathic Arthritis
Abstract Number: 814

Results Of a Randomised Controlled Trial Comparing Tight Control Of Early Psoriatic Arthritis (TICOPA) With Standard Care: Tight Control Improves Outcome
Abstract Number: 1943

Results of a Reliability Exercise for the Grading of Tendon Rupture in Patients With Rheumatoid Arthritis, using a Consensus-Based Ultrasound Score
Abstract Number: 2691

Results Of The Strass Trial Regarding Impact Of Progressive Spacing Of Tnf-Blocker Injections In Rheumatoid Arthritis Patients In Das28 Remission: Is There a Difference Between Drugs – Adalimumab and Etanercept – Or Their Mode Of Use – Monotherapy Or Combination?
Abstract Number: 1345

Retinal Vascular Calibre – a Novel Biomarker Of Inflammation and Treatment Response In Rheumatoid Arthritis
Abstract Number: 2782

Retreatment With Rituximab In The Rituximab In ANCA-Associated Vasculitis (RAVE) Trial

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].